WHY NOVUS CAPITAL?

Novus Capital Limited is an investment and financial services company specialising in Investment Banking, Corporate Advisory and Share Trading services for Australian corporate and private clients, and overseas corporate clients.

RECENTLY VISITED
CONTACT INFO

Electrogenics Laboratories Limited

Electrogenics Laboratories Limited

Series C Capital Raise

For professional and s708 investors only

Electrogenics Laboratories Limited is an unlisted Australian company who have developed the MOSkin™ radiation dosimetry system, the next generation radiation dosimeter for cancer patients enters the final stages.The Company is offering a limited opportunity for eligible investors to participate in its Series C raise, before the anticipated commencement of Sales in the USA, targeted for Q2 2025 (subject to FDA approval).

Summary of Offer

  • Raise Amount: $1.2 million with the ability to take overs
  • Price per share: $0.065c (6.5 cents per share)
  • Pre-Money Valuation $12 Million

Offer Closes: (AEDT) 5:00PM on 27 December 2024
All dates subject to change without notice.

Downloads

Electrogenics Series C Termsheet
Electrogenics Series C Presentation
Electrogenics Research Report

Deal Contact

Online Application

By agreeing you are stipulating that you have read the Declaration below and are agreeing to be bound by it.

Pre-filled for convenience - change as required.
Min Investment: $
Max Investment: $

Your Bank Details (optional) - In case we need to refund

Declaration

By submitting this completed application form, applicants (Applicants) for shares in Electrogenics Laboratories Limited (The Company) do hereby agree:

  1. that this will constitute their unqualified acceptance of the offer to subscribe for shares in The Company and that they have entered an irrevocable commitment to pay for the shares in clear funds.
  2. to transfer in clear funds the investment value of shares applied for above, simultaneously, or as soon as practical from the date of the application to the bank account on this form.
  3. to henceforth be bound by the constitution of The Company.
  4. That they will be taken to have represented and warranted in favour of The Company that they are "professional" or "sophisticated" investors for the purposes of section 761G(7) of either of the exclusions defines within the Financial Markets Conduct Act 2013 (Schedule 1, clauses 3(2)(a) to (d) or 3(3)(a)) or sections 708(8) or (11) of the Corporations Act 2001 and will, when required, provide evidence of this status in a form that is reasonably acceptable to The Company.
  5. That they acknowledge that they will not be provided with a disclosure document as defined under the Corporations Act in relation to the Offer. That they have not been provided with any information and no representations have been made to me and no warranties have been given to them by or on behalf of the Company in relation to this Offer. They have undertaken their own investigations into the Company and have not relied on any information provided to them by the Company, or on any recommendations, representations or warranties made by any person in relation to this Offer. The Offer is made to them only on the basis of the accuracy of this application.
  6. That they acknowledge that The Company intends to apply to a recognised stock exchange for listing at a future date and that the company and or the regulator may require that some or all these shares may be subject to escrow of up to a maximum of 2 years from the date of quotation on the exchange.
  7. That they acknowledge that they have considered whether to consult with their legal advisor or financial advisor if they require independent advice in relation to the offer to apply for The Company shares or to make such other enquiries as they deem necessary.
  8. That they acknowledge that they have considered and formed their own judgement on the advisability of an investment in The Company shares considering the potential risks relating thereto, some of which are set out in an information memorandum which is available on request.
  9. Unless otherwise agreed, that they acknowledge that the Directors of The Company may scale back or reject this application in full and refund any monies due without interest.

Payment details and instructions

Submission of this form will constitute acceptance of the number of shares stated on this form. If an Application Form is not completed correctly it may still be accepted. Any decision of the directors as to whether to accept an application form and how to construe, amend or complete it, shall be final.

Once you have submitted this form you will be taken to a page that will provide full instructions and details for making your payment.

You should transfer funds via electronic direct credit to the account indicated. You MUST include the Reference (provided on next page) as the payment reference when submitting your payment. Failure to do so may result in your application not being processed.